OPTH$2.29+2.23%
Optimi Health Corp.
Sector: Pharmaceutical PreparationsIndustry: Drug Manufacturers - Specialty & GenericCountry: CAExchange: Nasdaq
Mkt Cap:$13.11M
Float & O/S:
Inst Own:
DilutionScan read 28 of Optimi Health Corp.'s SEC filings and found 10 warrant series, 3 convertibles, 1 equity line, 2 S-1 registrations and 1 completed offering on file for OPTH. The latest dilution event on file is a registration statement on Aug 25, 2026. Analysis updated Sep 28, 2026.
Signal8 Summary
OPTH
Negative gross margin and reverse split
Snapshot
Optimi Health is a tiny psychedelic manufacturer with deeply negative unit economics. FY 2025 revenue was just $301K, but the company posted a negative gross margin of -486%, meaning it cost far more to produce its drugs than it sold them for.
What's Happening Right Now
- : Optimi completed its third commercial shipment of 5mg psilocybin capsules to Australia for treatment-resistant depression under the Authorized Prescriber Scheme.
- : The company completed its first export of naturally derived psilocybin to the United Kingdom to support a planned Phase 2 clinical trial.
- : Optimi secured naturally derived ibogaine from two sources and will commence development of finished drug products at its facility this summer.
- : Australia's Therapeutic Goods Administration updated its Authorized Prescriber framework to broaden therapist eligibility and allow treatment in non-hospital settings.
- : Optimi Health priced a $15 million public offering at $6.25 per share alongside a 1-for-30 reverse stock split and uplisting to the Nasdaq Capital Market.
